Spots Global Cancer Trial Database for taxanes
Every month we try and update this database with for taxanes cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | NCT00270413 | Metastatic Brea... | SU11248 | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549 | Neoplasms | Nilotinib and P... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | NCT00437749 | Non-Small Cell ... | CBT-1 Placebo | 18 Years - | CBA Research | |
| Lenalidomide and Paclitaxel in Prostate Cancer | NCT00933426 | Prostate Cancer | Lenalidomide Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | NCT06217185 | HER2-positive B... Advanced Breast... | Pyrotinib Trastuzumab Taxanes Capecitabine | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | NCT00270413 | Metastatic Brea... | SU11248 | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | NCT00050167 | Breast Cancer | Paclitaxel Docetaxel Capecitabine | - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer | NCT02027428 | Squamous Cell C... | Abraxane (Induc... Carboplatin (In... Abraxane (Maint... Best Supportive... Abraxane (Induc... Carboplatin (In... Best Supportive... | 18 Years - | Celgene | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies | NCT00256191 | Neoplasms Hodgkin's Disea... Non-Hodgkin's L... | TPI 287 Injecti... | 18 Years - 85 Years | Cortice Biosciences, Inc. | |
| Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer | NCT02506361 | Breast Cancer | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | ||
| TPI 287 in Patients With Recurrent Glioblastoma Multiforme | NCT01113463 | Brain Cancer | TPI 287 | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide and Paclitaxel in Prostate Cancer | NCT00933426 | Prostate Cancer | Lenalidomide Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Biweekly Docetaxel in Patients With Metastatic Breast Cancer. | NCT02041351 | Metastatic Brea... | Docetaxel | 21 Years - 85 Years | Centro Universitario contra el Cáncer | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| Evaluation of the Effect of Laser Acupuncture on Taxane Acute Pain Syndrome Patients | NCT04872556 | Pain Cancer Joint Pain | Laser acupunctu... Pseudo-laser ac... | 20 Years - 70 Years | Chang Gung Memorial Hospital | |
| Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer | NCT02455141 | Breast Neoplasm | Epirubicin plus... Taxanes Taxanes plus Ca... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | NCT01276899 | Triple Negative... | Needle core bio... Needle core bio... | 18 Years - | Jewish General Hospital | |
| Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | NCT04449549 | Neoplasms | Nilotinib and P... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients | NCT01276899 | Triple Negative... | Needle core bio... Needle core bio... | 18 Years - | Jewish General Hospital | |
| A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | NCT00437749 | Non-Small Cell ... | CBT-1 Placebo | 18 Years - | CBA Research | |
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | NCT00050167 | Breast Cancer | Paclitaxel Docetaxel Capecitabine | - | M.D. Anderson Cancer Center | |
| TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) | NCT04760431 | HER2-positive B... Brain Metastase... | Trastuzumab Taxanes Pertuzumab Tyrosine kinase... | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | NCT00050167 | Breast Cancer | Paclitaxel Docetaxel Capecitabine | - | M.D. Anderson Cancer Center | |
| Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | NCT04290793 | Breast Cancer | Pyrotinib Epirubicin Cyclophosphamid... Taxanes Trastuzumab | 18 Years - 65 Years | Hebei Medical University Fourth Hospital | |
| A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients | NCT00659269 | Cancer | Multivitamin (M... Multivitamin + ... Chemotherapy | 18 Years - | New Mexico Cancer Care Alliance | |
| Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer | NCT01296243 | Prostate Cancer | Tesetaxel | 18 Years - | Genta Incorporated | |
| Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer | NCT02506361 | Breast Cancer | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | ||
| Chemotherapy-Induced Peripheral Neuropathy Survey | NCT01016028 | Breast Cancer Colorectal Canc... Myeloma Chemotherapy-in... | Questionnaire Sensory Tests Interview | 18 Years - | M.D. Anderson Cancer Center | |
| Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer | NCT01296243 | Prostate Cancer | Tesetaxel | 18 Years - | Genta Incorporated |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
